Evidence map›Paper›PMID 38321619›Full record

ArticleAdvanced healthcare materials2024

Antimicrobial Guanidinylate Polycarbonates Show Oral In Vivo Efficacy Against Clostridioides Difficile.

Menglin Xue, Soumyadeep Chakraborty, Ruixuan Gao, Shaohui Wang, Meng Gu, Ning Shen, Lulu Wei, Chuanhai Cao, Xingmin Sun, Jianfeng Cai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Development of Low-Toxicity Antimicrobial Polycarbonates Bearing Lysine Residues.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Menglin XueDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, 33620, USA.
Soumyadeep ChakrabortyDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.
Ruixuan GaoDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, 33620, USA.
Shaohui WangDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.
Meng GuDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, 33620, USA.
Ning ShenDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, 33620, USA.
Lulu WeiDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, 33620, USA.
Chuanhai CaoDepartment of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL, 33612, USA.
Xingmin SunDepartment of Molecular Medicine, Morsani College of Medicine, University of South Florida, 12901 Bruce B Downs Blvd, Tampa, FL, 33612, USA.
Jianfeng CaiDepartment of Chemistry, University of South Florida, 4202 E. Fowler Ave., Tampa, FL, 33620, USA.ORCID 0000-0003-3106-3306

Funding

Multivalent vaccines against Clostridium difficile infectionR01AI132711 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI Xingmin Sun, Shifeng Wang · 2017 to 2026
$3.3M
Novel polymer biomaterials combating C. difficile infectionR01AI149852 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG, SUN, XINGMIN · 2019 to 2023
$1.9M
Antimicrobial agents derived from AApeptide biomaterialsR01AI152416 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CAI, JIANFENG · 2020 to 2024
$1.9M
NIAID NIH HHS R01 AI132711NIAID NIH HHS R01 AI149852NIAID NIH HHS R01 AI152416NIH HHS 5R01AI149852NIH HHS 5R01AI152416NIH HHS R01AI132711
6 · The paper itself

Abstract

The emerging antibiotic resistance has been named by the World Health Organization (WHO) as one of the top 10 threats to public health. Notably, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VREF) are designated as serious threats, whereas Clostridioides difficile (C. difficile) is recognized as one of the most urgent threats to human health and unmet medical need. Herein, they report the design and application of novel biodegradable polymers - the lipidated antimicrobial guanidinylate polycarbonates. These polymers showed potent antimicrobial activity against a panel of bacteria with fast-killing kinetics and low resistance development tendency, mainly due to their bacterial membrane disruption mechanism. More importantly, the optimal polymer showed excellent antibacterial activity against C. difficile infection (CDI) in vivo via oral administration. In addition, compared with vancomycin, the polymer demonstrated a much-prolonged therapeutic effect and virtually diminished recurrence rate of CDI. The convenient synthesis, easy scale-up, low cost, as well as biodegradability of this class of polycarbonates, together with their in vitro broad-spectrum antimicrobial activity and orally in vivo efficacy against CDI, suggest the great potential of lipidated guandinylate polycarbonates as a new class of antibacterial biomaterials to treat CDI and combat emerging antibiotic resistance.

Indexed as

Clostridioides difficilePolycarboxylate CementAdministration, OralAnimalsAnti-Bacterial AgentsAnti-Infective AgentsClostridium InfectionsGuanidinesMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsAnti-Infective AgentsGuanidinespolycarbonatePolycarboxylate Cementantimicrobial agentsC. difficilehost‐defense peptidespolycarbonates

Identifiers

PMID38321619
PMCPMC11144102

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.